Syros Pharmaceuticals Inc (SYRS)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Nancy A. Simonian
Employees:
76
620 MEMORIAL DRIVE, SUITE 300, CAMBRIDGE, MA 02139
617-744-1340

Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. Its platform identifies the master switches for disease genes, opening a whole new approach to novel therapeutics. The company focuses on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. Syros Pharmaceuticals was founded by Richard A. Young, Nathanael S. Gray and James E. Bradner in 2012 and is headquartered in Cambridge, MA.

Data derived from most recent annual or quarterly report
Market Cap 55.316 Million Shares Outstanding62.083 Million Avg 30-day Volume 1.112 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.59
Price to Revenue3.0983 Debt to Equity0.6448 EBITDA-89.614 Million
Price to Book Value1.1915 Operating Margin-435.72610000000003 Enterprise Value2.31 Million
Current Ratio4.221 EPS Growth0.066 Quick Ratio3.996
1 Yr BETA 1.5553 52-week High/Low 5.77 / 0.65 Profit Margin-403.9954
Operating Cash Flow Growth-35.1344 Altman Z-Score-5.1696 Free Cash Flow to Firm -96.147 Million
Earnings Report2022-08-04
View SEC Filings from SYRS instead.

View recent insider trading info

Funds Holding SYRS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding SYRS BETA

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-06-07:
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-08:
    Item 1.01: Entry into a Material Definitive Agreement
  • 8-K: filed on 2022-01-10:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-10-13:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-09-20:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-09-10:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-06-10:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2021-05-26:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-02-25:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-01-20:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    WIRTH PETER

    • Director
    17,500 2022-06-01 1

    SHARP PHILLIP A

    • Director
    17,500 2022-06-01 1

    AKKARAJU SRINIVAS

    • Director
    17,500 2022-06-01 1

    FANUCCI MARSHA

    • Director
    17,500 2022-06-01 1

    DUNSIRE DEBORAH

    • Director
    17,500 2022-06-01 3

    YOUNG RICHARD A

    • Director
    17,500 2022-06-01 1

    ALLES MARK J

    • Director
    17,500 2022-06-01 1

    NASHAT AMIR

    • Director
    17,500 2022-06-01 1

    ECKHARDT SUE GAIL

    • Director
    17,500 2022-06-01 1

    SIMONIAN NANCY A PRESIDENT & CEO

    • Officer
    • Director
    692,723 2022-04-01 2

    ROTH DAVID CHIEF MEDICAL OFFICER

    • Officer
    59,719 2022-04-01 2

    OLSON ERIC R CHIEF SCIENTIFIC OFFICER

    • Officer
    59,734 2022-04-01 4

    STEPHENS KRISTIN CHIEF DEVELOPMENT OFFICER

    • Officer
    30,885 2022-04-01 2

    CHEE CONLEY CHIEF COMMERCIAL OFFICER

    • Officer
    180,000 2022-02-15 3

    HAAS JASON CHIEF FINANCIAL OFFICER

    • Officer
    205,000 2022-02-15 3

    QUIRK GERALD E CHIEF LEGAL & ADMIN. OFFICER

    • Officer
    0 2021-02-17 0

    SPRINGHORN JEREMY P. CHIEF BUSINESS OFFICER

    • Officer
    0 2021-02-17 0

    FERRA JOSEPH J JR CHIEF FINANCIAL OFFICER

    • Officer
    0 2021-02-17 0

    ARCH VENTURE FUND VII, L.P.

    ARCH VENTURE PARTNERS VII, L.P.

    ARCH VENTURE PARTNERS VII, LLC

    CRANDELL KEITH

    BYBEE CLINTON

    NELSEN ROBERT

    • 10% Owner
    No longer subject to file 2019-07-15 0

    SATO VICKI L

    • Director
    0 2019-06-11 0

    BONNEY MICHAEL W

    • Director
    0 2019-06-11 0

    SHAW ALICE TSANG

    • Director
    0 2019-06-11 0

    AFEYAN NOUBAR

    • 10% Owner
    0 2017-12-31 0

    DESIMONE COLLEEN ELIZABETH PRINCIPAL ACCOUNTING OFFICER

    • Officer
    0 2017-10-23 0

    FLAGSHIP VENTURES FUND IV, L.P.

    FLAGSHIP VENTURES FUND IV-RX, L.P.

    FLAGSHIP VENTURELABS IV, LLC

    FLAGSHIP VENTURES FUND IV GENERAL PARTNER LLC

    AFEYAN NOUBAR

    KANIA EDWIN M JR

    • 10% Owner
    3,253,491 2017-08-17 0

    NELSEN ROBERT

    • Director
    • 10% Owner
    0 2017-06-08 0

    PATEL SANJ K

    • Director
    0 2017-06-08 0

    KUVALANKA KYLE D. CHIEF OPERATING OFFICER

    • Officer
    0 2017-02-10 0

    BANCEL STEPHANE

    • Director
    0 2016-09-15 0

    FLYNN JAMES E

    DEERFIELD MGMT L.P.

    DEERFIELD MANAGEMENT CO

    DEERFIELD SPECIAL SITUATIONS FUND, L.P.

    DEERFIELD MGMT III, L.P.

    DEERFIELD PRIVATE DESIGN FUND III, L.P.

    • 10% Owner
    • POSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUP
    2,095,220 2016-07-06 0

    AISLING CAPITAL III LP

    AISLING CAPITAL PARTNERS III LP

    AISLING CAPITAL PARTNERS III LLC

    ELMS STEVE

    SCHIFF ANDREW N

    PURCELL DENNIS J

    • 10% Owner
    No longer subject to file 2016-07-06 0

    ARCH VENTURE FUND VII LP

    ARCH VENTURE PARTNERS VII, L.P.

    ARCH VENTURE PARTNERS VII, LLC

    CRANDELL KEITH

    BYBEE CLINTON

    • 10% Owner
    4,637,137 2016-07-06 0

    REDMILE GROUP, LLC

    GREEN JEREMY

    • 10% Owner
    No longer subject to file 2016-07-06 0

    POLARIS MANAGEMENT CO. VII, L.L.C.

    POLARIS PARTNERS VII, L.P.

    POLARIS ENTREPRENEURS' FUND VII, L.P.

    • 10% Owner
    No longer subject to file 2016-07-06 0

    WUXI HEALTHCARE VENTURES II, L.P.

    • 10% Owner
    No longer subject to file 2016-07-06 0

    WUXI PHARMTECH HEALTHCARE FUND I L.P.

    • 10% Owner
    No longer subject to file 2016-07-06 0

    GRAY NATHANAEL

    • 10% Owner
    426,666 2016-06-29 0

    CONDE JORGE CHIEF STRATEGY OFFICER

    • Officer
    0 2016-06-29 0

    JEB SYROS TRUST

    • 10% Owner
    351,666 2016-06-29 0

    PERSPECTA TRUST LLC

    • 10% Owner
    351,666 2016-06-29 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    ALLES MARK J - Director

    2022-06-02 19:06:18 -0400 2022-06-01 A 17,500 a 17,500 direct

    SHARP PHILLIP A - Director

    2022-06-02 19:08:34 -0400 2022-06-01 A 17,500 a 17,500 direct

    NASHAT AMIR - Director

    2022-06-02 19:08:03 -0400 2022-06-01 A 17,500 a 17,500 direct

    FANUCCI MARSHA - Director

    2022-06-02 19:07:35 -0400 2022-06-01 A 17,500 a 17,500 direct

    ECKHARDT SUE GAIL - Director

    2022-06-02 19:07:06 -0400 2022-06-01 A 17,500 a 17,500 direct

    AKKARAJU SRINIVAS - Director

    2022-06-02 19:10:22 -0400 2022-06-01 A 17,500 a 17,500 direct

    YOUNG RICHARD A - Director

    2022-06-02 19:09:36 -0400 2022-06-01 A 17,500 a 17,500 direct

    WIRTH PETER - Director

    2022-06-02 19:09:01 -0400 2022-06-01 A 17,500 a 17,500 direct

    DUNSIRE DEBORAH - Director

    2022-06-02 19:10:54 -0400 2022-06-01 A 17,500 a 17,500 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    SYROS PHARMACEUTICALS INC SYRS 2022-06-24 22:15:03 UTC 0.1242 1.4458 55000
    SYROS PHARMACEUTICALS INC SYRS 2022-06-24 21:45:03 UTC 0.1242 1.4458 55000
    SYROS PHARMACEUTICALS INC SYRS 2022-06-24 21:15:04 UTC 0.1242 1.4458 55000
    SYROS PHARMACEUTICALS INC SYRS 2022-06-24 20:45:03 UTC 0.1538 1.4162 55000
    SYROS PHARMACEUTICALS INC SYRS 2022-06-24 20:15:03 UTC 0.1538 1.4162 55000
    SYROS PHARMACEUTICALS INC SYRS 2022-06-24 19:45:03 UTC 0.1538 1.4162 55000
    SYROS PHARMACEUTICALS INC SYRS 2022-06-24 19:15:03 UTC 0.1538 1.4162 55000
    SYROS PHARMACEUTICALS INC SYRS 2022-06-24 18:45:03 UTC 0.1515 1.4185 55000
    SYROS PHARMACEUTICALS INC SYRS 2022-06-24 18:15:04 UTC 0.1515 1.4185 55000
    SYROS PHARMACEUTICALS INC SYRS 2022-06-24 17:45:03 UTC 0.1515 1.4185 55000
    SYROS PHARMACEUTICALS INC SYRS 2022-06-24 17:15:03 UTC 0.1515 1.4185 55000
    SYROS PHARMACEUTICALS INC SYRS 2022-06-24 16:45:03 UTC 0.1395 1.4305 55000
    SYROS PHARMACEUTICALS INC SYRS 2022-06-24 16:15:03 UTC 0.1395 1.4305 55000
    SYROS PHARMACEUTICALS INC SYRS 2022-06-24 15:45:03 UTC 0.1395 1.4305 20000
    SYROS PHARMACEUTICALS INC SYRS 2022-06-24 15:15:03 UTC 0.1395 1.4305 20000
    SYROS PHARMACEUTICALS INC SYRS 2022-06-24 14:45:03 UTC 0.2535 1.3165 20000
    SYROS PHARMACEUTICALS INC SYRS 2022-06-24 14:15:03 UTC 0.2535 1.3165 20000
    SYROS PHARMACEUTICALS INC SYRS 2022-06-24 13:45:03 UTC 0.2535 1.3165 20000
    SYROS PHARMACEUTICALS INC SYRS 2022-06-24 13:15:03 UTC 0.2535 1.3165 20000
    SYROS PHARMACEUTICALS INC SYRS 2022-06-24 12:45:03 UTC 0.2535 1.3165 20000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    Elevate your investments